GlaxoSmithKline announces Q4 2010 legal charge
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that it expects to record a legal charge for the fourth quarter of 2010 of £2.2 billion ($3.4 billion) (equating to an after tax cost of £1.8 billion).
European Commission Clears Acquisition of Genzyme Corporation by sanofi-aventis
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the European Commision has cleared sanofi-aventis' proposed acquisition of Genzyme Corporation unconditionally under EU merger control rules.
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.
Sandoz announces phase II clinical trial for biosimilar version of rituximab
- Details
- Category: Novartis
Sandoz announced that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche's Rituxan® / Mabthera®), a leading monoclonal antibody indicated in conditions including non-Hodgkin's lymphoma and rheumatoid arthritis.
GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK'786
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. announced that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.
New Bayer U.S. Innovation Center starts its operations
- Details
- Category: Bayer
The U.S. Innovation Center of Bayer HealthCare's pharmaceutical division has started its operations in San Francisco's Mission Bay life sciences hub. At the same time the company announced a master agreement for research collaborations with the University of California, San Francisco (UCSF).
People to Actively Manage Their Type 2 Diabetes
- Details
- Category: Bristol-Myers Squibb
The American Association of Clinical Endocrinologists (AACE) and its educational arm - the American College of Endocrinology (ACE) - in partnership with Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), announced a new public health initiative for people with type 2 diabetes mellitus called The Type 2 Talk:
More Pharma News ...
- Genzyme Financial Recovery Continues in Fourth Quarter
- Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse®
- Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold
- Genzyme Statement on Discussions With Sanofi-Aventis
- US Food and Drug Administration extend review timeline for vandetanib
- KOMBIGLYZE™ XR Now Available in U.S. Pharmacies
- FDA grants supplemental approval for ACTEMRA